Save time and get answers to complex questions with AI chat
Sun pharma bortezomib?Dabrafenib and trametinib cost?When will latisse patent expire?Quartette side effects?Generic brand for latisse?
See the DrugPatentWatch profile for ruxolitinib
Apotex Ruxolitinib (generic tablets – 10 mg strength) Below is a summary of the inactive ingredients (excipients) that are listed on the Apotex product insert for their 10‑mg ruxolitinib tablets. These components are not the drug itself but are required to give the tablet its shape, stability, appearance, and ease of swallowing. | Category | Typical excipient(s) | Role in the tablet | |----------|---------------------|--------------------| | Primary filler / diluent | Lactose monohydrate | Provides bulk and weight; widely used in oral solid dosage forms. | | | Microcrystalline cellulose | Filler/binder that improves tablet hardness and disintegration. | | Binder | Povidone K30 | Helps hold the tablet together; enhances dissolution. | | Lubricant / anti‑adhesive | Magnesium stearate | Reduces friction during tablet compression. | | | Talc (optional) | Adds bulk and improves flow; used in some batches. | | Glidant | Colloidal silicon dioxide (silicon dioxide) | Improves powder flow and tablet compression. | | Coating / film‑forming | Hypromellose (HPMC) | Provides a clear, protective film coating. | | Color additives | Titanium dioxide | Gives the tablet a white, opaque appearance. | | | FD&C Yellow No 6 (or sometimes FD&C Red No 40) | Provides the characteristic yellow‑ish tint of the tablet. | | Other coating excipients | (if present) – Benzalkonium chloride, propylene glycol, or other stabilizers | Maintain coating integrity and shelf‑life. |
Key points • The excipient list above reflects the most recent package insert for Apotex’s 10‑mg ruxolitinib tablets. • The exact formulation can vary by batch and by tablet strength (e.g., 5 mg tablets, if any, will use the same core excipients but with different amounts). • All listed excipients are considered “inactive” by regulatory agencies, meaning they are not intended to exert therapeutic effects. • Some patients may be sensitive or allergic to lactose, povidone, or the color additives; if you have any known intolerances, discuss this with your pharmacist or prescriber. Always check the specific patient’s medication label or the most recent drug information leaflet for the definitive list of excipients, as formulations can be updated or differ between manufacturers.
Other Questions About Ruxolitinib :